Search Results for: "amgen v coherus"

Updates on Coherus pegfilgrastim and other biosimilar efforts

We previously posted that Coherus had filed a motion to stay discovery in Amgen v. Coherus (involving pegfilgrastim) pending resolution of Coherus’s motion to dismiss.  On September 13, Coherus withdrew its motion to stay.  The court subsequently entered a scheduling order, setting a 5-day trial starting September 16, 2019. Meanwhile,…

Read More

BPCIA Litigation Roundup (Fall 2017)

Below is our fall update on the U.S. patent litigations concerning proposed or approved biosimilar products. For additional details, please consult our BPCIA Litigation Summary Chart or our previous quarterly updates (Summer 2016, Fall 2016, Midwinter 2017, Spring 2017, Summer 2017).

Read More

BPCIA Litigation Roundup (Spring 2017)

Below is our spring update on the U.S. patent litigations concerning proposed or approved biosimilar products. For additional details, please consult our BPCIA Litigation Summary Chart or our previous quarterly updates (Summer 2016, Fall 2016, Midwinter 2017).

Read More

New BPCIA Litigation: Amgen v. Coherus (D. Del.)

Amgen has filed a BPCIA suit in the District of Delaware against Coherus Biosciences, Inc., alleging infringement of U.S. Patent No. 8,273,707—a patent “directed to a process for purifying proteins.”  The complaint alleges that following FDA’s acceptance of Coherus’s abbreviated biologics application for a biosimilar version of Amgen’s Neulasta® (pegfilgrastim)…

Read More

12